LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 345 of 535
Next
>>
>
8601 to 8625 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	Dactolisib	3.33	uM	LJP5	3	M14	72	hr	1097	1196	3925	0.3047	0.0480
BT-20	Dactolisib	10	uM	LJP5	1	M13	72	hr	1097	1539	3735	0.4120	0.2110
BT-20	Dactolisib	10	uM	LJP5	2	M13	72	hr	1097	1300	3877	0.3352	0.0976
BT-20	Dactolisib	10	uM	LJP5	3	M13	72	hr	1097	1429	3925	0.3640	0.1545
BT-20	Alpelisib	0.04	uM	LJP5	1	N06	72	hr	1097	4305	3735	1.1525	1.1673
BT-20	Alpelisib	0.04	uM	LJP5	2	N06	72	hr	1097	4307	3877	1.1107	1.1187
BT-20	Alpelisib	0.04	uM	LJP5	3	N06	72	hr	1097	3559	3925	0.9067	0.8962
BT-20	Alpelisib	0.12	uM	LJP5	1	N05	72	hr	1097	3755	3735	1.0053	1.0060
BT-20	Alpelisib	0.12	uM	LJP5	2	N05	72	hr	1097	4085	3877	1.0534	1.0580
BT-20	Alpelisib	0.12	uM	LJP5	3	N05	72	hr	1097	3585	3925	0.9133	0.9037
BT-20	Alpelisib	0.37	uM	LJP5	1	N04	72	hr	1097	2943	3735	0.7879	0.7476
BT-20	Alpelisib	0.37	uM	LJP5	2	N04	72	hr	1097	3383	3877	0.8724	0.8556
BT-20	Alpelisib	0.37	uM	LJP5	3	N04	72	hr	1097	2546	3925	0.6486	0.5805
BT-20	Alpelisib	1.11	uM	LJP5	1	N03	72	hr	1097	2198	3735	0.5885	0.4816
BT-20	Alpelisib	1.11	uM	LJP5	2	N03	72	hr	1097	2144	3877	0.5529	0.4445
BT-20	Alpelisib	1.11	uM	LJP5	3	N03	72	hr	1097	1908	3925	0.4861	0.3510
BT-20	Alpelisib	3.33	uM	LJP5	1	N02	72	hr	1097	1109	3735	0.2969	0.0060
BT-20	Alpelisib	3.33	uM	LJP5	2	N02	72	hr	1097	1430	3877	0.3688	0.1565
BT-20	Alpelisib	3.33	uM	LJP5	3	N02	72	hr	1097	1184	3925	0.3016	0.0422
BT-20	Alpelisib	10	uM	LJP5	1	N01	72	hr	1097	733	3735	0.1962	-0.2041
BT-20	Alpelisib	10	uM	LJP5	2	N01	72	hr	1097	799	3877	0.2061	-0.1598
BT-20	Alpelisib	10	uM	LJP5	3	N01	72	hr	1097	742	3925	0.1890	-0.1916
BT-20	GDC-0980	0.04	uM	LJP5	1	K24	72	hr	1097	1389	3735	0.3719	0.1427
BT-20	GDC-0980	0.04	uM	LJP5	2	K24	72	hr	1097	1267	3877	0.3267	0.0822
BT-20	GDC-0980	0.04	uM	LJP5	3	K24	72	hr	1097	1550	3925	0.3949	0.2067

|<
<<
Previous
Page 345 of 535
Next
>>
>
8601 to 8625 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)